Commitment and collaboration

Together, we are committed to making a difference – to patients, the healthcare system and the society in which we are embedded.

Basilea at a glance

Basilea is a revenue-generating, commercial-stage Swiss biopharmaceutical company. Our activities are focused in the areas of hospital antibiotics and hospital antifungals. Our portfolio comprises of two marketed anti-infective brands (Cresemba® and Zevtera®) and several preclinical anti-infective assets. We are building on our potential for sustainable growth and valuation generation, based on increasing revenues and selective investments into internal and external innovation. Basilea was founded in 2000 and is located in the life sciences hub of the Basel area. Basilea has about 150 employees. Since 2004, Basilea is listed on the SIX Swiss Stock Exchange with the ticker symbol BSLN.

Vision and mission

People are at the heart of everything we do. We strive towards making a difference to patients. With expertise, care and persistence. We aim to be a leading provider of innovative medicines. For the benefit of patients.

Organization

Board of directors

Board of directors as of December 31, 2022

Domenico Scala

Chairman of the board

Thomas Werner, Ph.D.

Vice-chairman of the board of directors

Martin Nicklasson, Ph.D.

Member of the board of directors

Nicole Onetto, M.D.

Member of the board of directors

Leonard Kruimer

Member of the board of directors

Steven D. Skolsky

Member of the board of directors

Board committees

Audit committee	Compensation committee	Corporate governance & nomination committee
Leonard Kruimer (Chairman)	Dr. Martin Nicklasson (Chairman)	Dr. Thomas Werner (Chairman)
Dr. Martin Nicklasson	Dr. Nicole Onetto	Domenico Scala
Steven D. Skolsky	Dr. Thomas Werner	Steven D. Skolsky